Formycon AG announces licensing agreements for Eylea biosimilar FYB203 commercialization in Australia and Latin America
Formycon AG has announced that Klinge Biopharma GmbH has signed exclusive licensing agreements with Actor Pharmaceuticals for Australia and Megalabs S.A. for Latin America regarding the commercialization of Formycon’s Eylea® biosimilar FYB203. Klinge will receive upfront and milestone payments, along with royalties on net sales, while Formycon will manage the supply chain and receive additional service payments. This strategic move enhances Formycon's market presence in these regions.
Formycon AG announced that Klinge Biopharma GmbH, the exclusive owner of global commercialization rights for Formycon’s Eylea® biosimilar FYB203 (aflibercept), has concluded exclusive license agreements with Actor Pharmaceuticals Pty. Ltd. for Australia and Megalabs S.A. for Latin America. Under these agreements, Klinge is eligible to receive upfront and milestone payments, as well as royalties on net sales, with Formycon participating in the mid-single-digit to low-double-digit percentage range of all payment streams to Klinge. Formycon will also act as an authorized designee to organize the supply chain for FYB203 and receive additional service payments and a volume-based profit component for commercial market supply on behalf of Klinge. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2213750_en), on October 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
